Filgen 30 Miu 300ug

Filgen 30 Miu 300ug contains the active ingredient Filgrastim. It is a recombinant human granulocyte colony-stimulating factor (G-CSF) used to stimulate the production and function of neutrophils, a type of white blood cell, in the body. Filgrastim is commonly prescribed to reduce the risk of infection in patients undergoing chemotherapy, to treat neutropenia (low neutrophil count), and to mobilize stem cells for transplantation.

Uses:

1. Chemotherapy-Induced Neutropenia: Filgen 30 Miu 300ug is indicated for the prevention of febrile neutropenia, a serious complication of chemotherapy characterized by a low neutrophil count and fever.
2. Neutropenia Treatment: It is used to treat neutropenia associated with various medical conditions, including chemotherapy, radiation therapy, bone marrow transplantation, and certain hematologic disorders.
3. Stem Cell Mobilization: Filgrastim may be used to stimulate the production and release of stem cells from the bone marrow into the bloodstream for collection and transplantation.

Mechanism of Action:

Filgrastim works by binding to and activating the G-CSF receptor on the surface of hematopoietic stem cells in the bone marrow. This stimulates the proliferation and differentiation of these cells into mature neutrophils, which play a crucial role in the body’s defense against infections.

Dosage and Administration:

• The dosage of Filgen 30 Miu 300ug and the frequency of administration depend on the specific indication, the patient’s medical condition, and other factors.
• It is usually administered by subcutaneous injection. The injection site may vary, but commonly used sites include the abdomen, thighs, or upper arms.
• Patients may be instructed to self-administer the injections after proper training by a healthcare professional.

Side Effects:

Common side effects of Filgrastim therapy may include bone pain, headache, fatigue, nausea, vomiting, diarrhea, fever, injection site reactions, and allergic reactions. Serious side effects such as spleen rupture, acute respiratory distress syndrome (ARDS), and capillary leak syndrome may occur rarely.

Precautions:

• Patients receiving treatment with Filgen 30 Miu 300ug should be monitored for signs of spleen enlargement, including left upper abdominal or shoulder pain.
• Filgrastim may increase the risk of splenic rupture, particularly in patients with pre-existing spleen enlargement or those receiving high doses of the medication.
• Patients with a history of allergic reactions to Filgrastim or E. coli-derived proteins should not use this medication.

Storage:

• Store Filgen 30 Miu 300ug in the refrigerator at the recommended temperature.
• Keep the vials or pre-filled syringes in the original packaging and protect them from light.